Edesa Biotech's Amendment No. 1: Key Updates in Annual Report 10-K for FY 2024

Here are the key insights extracted from the financial report section provided:

1. Company Identification:

• Name: Edesa Biotech, Inc.
• CIK Number: 0001540159
• Address: 100 Spy Court, Markham, ON, Canada, L3R 5H6.
• Common Shares: Without par value, traded on NASDAQ under ticker symbol EDSA.

2. Filing Information:

• This is an Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, initially filed on December 13, 2024.
• The amendment specifically revises Item 12 concerning "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" to disclose an additional shareholder owning more than 5% of common shares.

3. No Financial Impact:

• The amendment does not alter any previously reported financial results or reflect events occurring after the date of the Original Report.
• No financial statements are being filed with this Amendment, and thus, certifications under Section 906 of the Sarbanes-Oxley Act are not included.

4. Certifications:

• The amendment includes restated certifications by the Company's principal executive officer and principal financial officer, identified as Exhibits 31.3 and 31.4. However, specific paragraphs of these exhibits have been omitted as per SEC guidance.

5. Filing Status:

• The company is categorized as a Non-accelerated Filer.

6. Important Dates:

• Fiscal Year End: September 30, 2024
• Amendment Filing Date: Not explicitly mentioned but is linked to the Original Report filed on December 13, 2024.

7. Additional Context:

• It is emphasized that the amendment should be read in conjunction with the Original Report and other SEC filings by the Company.

This summary highlights the essential aspects of the filing, focusing on changes made, the implications of those changes, and the overall context of the report.